COMPARATIVE ANALYSIS OF ANTIPSYCHOTIC DRUG CONSUMPTION FOR TREATMENT OF SCHIZOPHRENIA IN THE IN-PATIENT HOSPITAL

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2019-02-07
Issue: 
2
Year: 
2019

L.B. Vaskova(1), T.V. Denisova(1), E.A. Maksimkina(1), M.V. Tiapkina(1), D.S. Dvoryak(2), V.P. Dukhovich(1) 1-I.M. Sechenov First Moscow State Medical University (Sechenov University); 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation 2-LDT «Pharmaceutical Research Associates CIS»; 5, Yauzskaya St., Moscow 109028, Russian Federation

Introduction. The problem of rational use of funds at all levels of medical care, including in the hospital sector, is very relevant. The prevalence of schizophrenia is up to 1% among the general population. The cost of treating schizophrenia in Russian Federation can reach 40% of the budget allocated for the treatment of mental illness. Reducing the economic burden can be achieved by optimizing the budget allocated to mental health services, namely due to the redistribution of funds within the hospital allowing to choose drugs with proven economic efficiency. Objective – comparative analysis of the consumption of antipsychotic drugs (APD) used to treat schizophrenia in the hospital. Material and methods. The study was conducted using the WHO ATC/DDD methodology by analyzing the copied of data from patient records (PR) of patients diagnosed with schizophrenia in 2012 (227 PR) and 2015 (198 PR). Results. During the study period, total consumption of APD decreased by 20%, while the consumption of atypical APD did not change, and the consumption of typical APD and APD of prolonged action decreased by ⅓, which may indicate a gradual replacement of typical APD with new generation drugs. Conclusion. In the studied hospital, the consumption of atypical APD remained at the same level. Some redistribution of consumption within this group was noted, consumption of typical APD and APD of prolonged action decreased by ⅓
Keywords: 
schizophrenia
neuroleptics
consumption
ATC/DDD WHO methodology
pharmacoeconomics
References: 
  1. Vaskova L.B., Tiapkina M.V. Study of drug consumption at the stationary stage of pharmaceutical care (ATC/DDD – WHO methodology). Guidelines. Moscow: 2015; 21 (in Russian).
  2. Vaskova L.B., Tiapkina M.V. The use of established daily doses in the analysis of the volume of consumption of drugs for the treatment of schizophrenia at the inpatient level of pharmaceutical care. «The main aspects of the development of megacities and pharmaceutical clusters, the preparation and improve-ment of pharmaceutical specialists». Conference materials in the framework of the XX Russian National Congress «Man and Medicine». Moscow, 2013; 15–7 (in Russian).
  3. Comprehensive mental health action plan for 2013–2020 WHA 66.8 (66th World Health Assembly, agenda item 13.3). WHО, 2013 (in Russian).
  4. The concept of development of the health care system in the Russian Federation until 2020. [Electronic resource]. Access mode: http://nrma.ru/Reform/zdr_conception_2020.shtml (in Russian).
  5. On the prospects for the development of mental health services in Moscow. Moskovskaуa meditsina, January 31, 2017. [Electronic resource]. Access mode: http://mosgorzdrav.ru/ru-RU/news/default/card/960.html (in Russian).
  6. The plan of activities of the Ministry of Health of the Russian Federation for 2013–2018. [Electronic resource]. Access mode: http://www.rosminzdrav.ru/ministry/programms/stranitsa-922 (in Russian).
  7. Vaskova L.B., Denisova Т.V., Tiapkina M.V., Kuznetsova Е.R. Consumption of drugs and an estimate of the cost of pharmacotherapy of patients with schizophrenia in the hospital. Farmatsiya, 2016; 65 (1): 28–31(in Russian).
  8. Zirjanov S.К., Belousov .Yu., Afanaseva Е.V., Efremova. А. Pharmacoeconomic analysis of the cost effectiveness of modern atypical antipsychotics in patients with schizophrenia. Kachestvennaуa klinicheskaуa praktika, 2013; 2: 18–32 (in Russian).
  9. Federal State Statistics Service. Central Statistical Database. [Electronic resource]. Access mode: http://www.gks.ru (in Russian).
  10. Federal guidelines for the use of drugs (formulary system). Release XVIII.Moscow: «Ekho», 2017; 847 (in Russian).
  11. Lyubov Е.B. et al. The economic burden of schizophrenia in Russia. Sotsial'naya i klinicheskaya psikhiatriya, 2012; 22 (3): 12–18. (in Russian).
  12. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2016. 19th edition. Oslo, 2015; 281.
  13. Vaskova L., Musina N., Tiapkina M. Comparative analysis of consumption of antipsychotic drugs for treating schizophrenia in hospitals in Russian Federation. Value in Health, 2016; 19 (7):528.